LifeCycle Project-Maternal Obesity and Childhood Outcomes Study Group IMPORTANCE Both low and high gestational weight gain have been associated with adverse maternal and infant outcomes, but optimal gestational weight gain remains uncertain and not well defined for all prepregnancy weight ranges.
G estational weight gain has been found to be related to the risk of pregnancy complications, maternal postpartum weight retention, and obesity in offspring.
1-3 Gestational weight gain reflects multiple characteristics, including maternal fat accumulation, fluid expansion, and the growth of the fetus, placenta, and uterus. 4 Gestational weight gain is necessary to ensure a healthy fetus, but excessive gestational weight gain has been associated with adverse outcomes. Higher prepregnancy body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) also has been associated with lower gestational weight gain and increased risk for adverse maternal and infant outcomes. Therefore, optimal gestational weight gain ranges should account for prepregnancy BMI. 5, 6 Existing guidelines for gestational weight gain from the US National Academy of Medicine (NAM; formerly the Institute of Medicine) have limitations such as the reliance on a limited number of observational studies relating gestational weight gain to 5 maternal and offspring outcomes and insufficient information about important pregnancy outcomes (eg, gestational hypertension and gestational diabetes). 7 In addition, the NAM guidelines do not include recommendations for obesity grade 1, 2, and 3 separately even though the prevalence of extreme obesity is increasing in Western populations. Information regarding optimal gestational weight gain across a range of maternal BMI categories is important for the identification of groups at increased risk. This study pooled individual participant data from 25 pregnancy and birth cohorts from Europe and North America to assess associations of the amount of gestational weight gain with maternal and infant outcomes according to baseline weight status of underweight, normal weight, overweight, obesity grade 1, obesity grade 2, and obesity grade 3.
Methods

Inclusion Criteria and Participating Cohorts
This study was part of an international LifeCycle Project collaboration on maternal obesity and childhood outcomes. 8, 9 A pregnancy or birth cohort study was eligible for inclusion if it included mothers with singleton live-born children who were born between 1989 and 2015, had information on maternal prepregnancy or early-pregnancy BMI, and had at least 1 offspring measurement (birth weight or childhood BMI). The final date of follow-up was December 2015. No exclusions were made based on previous pregnancy or birth complications.
The cohorts included had received institutional review board approval and written informed consent had been obtained. We invited 50 Western cohorts from Europe, North America, and Oceania that had been selected from existing collaborations on childhood health (the EarlyNutrition Project, the CHICOS Project, and Birthcohorts.net, which was accessed until July 2014), of which 39 cohorts agreed to participate. Only participants with information on maternal prepregnancy BMI, gestational weight gain, and at least 1 maternal or infant outcome of interest were included.
Of the 29 cohorts with the required data, 25 were populationbased cohorts and were included in the main study sample.
The remaining 4 hospital-based cohorts were included as the external validation sample (eFigure 1 in the Supplement). The included cohorts and the data collection methods appear in eTable 1 the Supplement. Women could be included more than once in the analyses if they had multiple singleton pregnancies during the study period. Anonymized data sets were stored on a single central secure data server that was only accessible by the main investigator analysts (E.V. and R.G.).
Maternal Prepregnancy BMI and Gestational Weight Gain
Maternal prepregnancy BMI was grouped into categories by 2 BMI units and clinical BMI groups according to World Health Organization definitions.
10 Data on total gestational weight gain in kilograms, which was defined as the difference between the latest weight before delivery and the prepregnancy weight, were provided by the cohorts. Gestational weight gain was grouped into categories of 2 kg each, ranging from weight loss to weight gain of 28 kg or greater. Smaller increments of gestational weight gain were not used because of insufficient statistical power among underweight and severely obese women. Categories at the extremes of gestational weight gain were combined for maternal underweight, obesity grade 2, and obesity grade 3. To be included, women were required to have data for maternal prepregnancy BMI, total gestational weight gain, and any adverse outcome (defined below).
Adverse Maternal and Infant Outcomes
The main outcome of the analyses was the composite any adverse outcome, which was defined as the presence of at least 1 of the following outcomes: preeclampsia, gestational hypertension, gestational diabetes, cesarean delivery, preterm birth, and small or large size for gestational age at birth. Preterm birth was defined as gestational age at birth of less than 37 weeks. Sex-and gestational age-adjusted SD scores for birth weight were calculated using a Northern European reference chart. 11 Small and large sizes for gestational age at birth were defined as sex-and gestational age-adjusted birth weight less than the 10th percentile and greater than the 90th percentile, respectively, within each cohort. For the sensitivity analyses, sex-and age-adjusted SD scores were calculated for childhood BMI based on reference growth charts from the World Health Organization. 12, 13 The SD scores were obtained using data from the highest age available for each child (median age, 84.9 months [quartile 1 and 3, 61.9 and 95.9 months]) and categorized as underweight, normal weight, and overweight or obesity (referred to as overweight) using World Health Organization cutoffs.
12,13
Statistical Analysis
Exploratory multilevel linear regression models were used to assess associations of maternal baseline characteristics with total gestational weight gain. The absolute risk for any adverse outcome was estimated across the full range of maternal prepregnancy BMI and gestational weight gain. Absolute risks were calculated as the percentage of women with any adverse outcome within each combination of BMI and gestational weight gain categories. Similarly, the absolute risks were estimated for any adverse outcome and for each individual outcome across the range of gestational weight gain categories within each clinical BMI group. The optimal gestational weight gain ranges per clinical BMI group were constructed. The odds ratios (ORs) for any adverse outcome were calculated for each gestational weight gain category within the particular clinical BMI group vs all other women within that BMI group. The individual-level data from all cohorts were analyzed simultaneously using multilevel models. The models followed a 2-level hierarchical structure with participants (level 1) nested within cohorts (level 2). We used a generalized linear mixed model with a binominal distribution and logit link. A random intercept at the cohort level was included to allow variation in the baseline risk for each cohort. Allowing a random slope for gestational weight gain did not improve the models. Model assumptions regarding linearity, independent errors, and influential values were met. Optimal gestational weight gain was defined as all weight gain categories with a statistically significant protective association (OR <1) for any adverse outcome.
14 If a gestational weight gain category with a nonsignificant association was between 2 significant estimates with an OR of less than 1, that category was included in the optimal gestational weight gain range. To construct easily interpretable optimal gestational weight gain ranges directly applicable for clinical practice, the main analyses were not adjusted for maternal age or parity. We also assessed continuous associations of maternal prepregnancy BMI and total gestational weight gain in SDs with any adverse outcome and compared the strength of these associations by using Z tests for the difference in ORs.
The following sensitivity analyses were performed: (1) we redefined the gestational weight gain ranges based on protective associations only (OR <1) regardless of statistical significance; (2) we adjusted the models for gestational age at birth and excluded preterm births because gestational weight gain depends on length of gestation; (3) we excluded participants with missing data on separate adverse maternal and infant outcomes; (4) we adjusted for maternal age and parity to explore whether optimal gestational weight gain ranges would change when maternal age and parity were taken into account; (5) we excluded cesarean delivery as an adverse outcome and included childhood underweight and overweight as adverse outcomes to explore whether optimal gestational weight gain ranges would change depending on the definition of the composite outcome; and (6) we excluded preeclampsia and gestational diabetes as outcomes to address possible reverse causation. We also constructed optimal gestational weight gain ranges during the first half of pregnancy, which were defined as the difference between weight at median gestational age of 15.4 weeks (quartile 1 and 3, 13.2 and 17.1 weeks) and prepregnancy weight using a similar approach.
The clinical performance of the gestational weight gain ranges in this study were assessed as secondary analyses and compared with the NAM guidelines by assessing the number of participants classified as having inadequate or excessive weight gain, the associations with adverse outcomes using binary logistic multilevel models, and the discriminative performance for both classification systems. The discriminative performance of the classification (the ability of the classification to discriminate between those with and those without the outcome) from this study and the NAM guidelines was assessed based on the area under the receiver operating characteristic curve (AUROC).
15 Predicted probabilities were obtained from binary logistic multilevel models assessing the associations of inadequate and excessive gestational weight gain with the outcomes. The predicted probabilities were used to calculate the AUROC. To assess the associations of the optimal gestational weight gain ranges with clinically relevant outcomes not used for the construction of the ranges, we also assessed low and high birth weight (≤2500 g or ≥4000 g). In addition, the clinical performance of both classification systems was assessed in the external validation sample (n = 3505). All statistical tests were 2-sided with a significance threshold of .05. However, the secondary analyses were not adjusted for multiple testing; therefore, these findings should be considered exploratory. All statistical analyses were performed using SPSS Statistics version 24.0 (IBM) and R version 3.3.3 (R Foundation for Statistical Computing).
Results
Participant Characteristics in Main Sample
Of the 29 cohorts with the required data (n = 200 175 participants), 25 were population-based cohorts (n = 196 670 women) and were included as the main study sample (median age, 30.0 years [quartile 1 and 3, 27.0 and 33.0 years] and 40 937 were white). At baseline, 7809 women (4.0%) were categorized as underweight (BMI <18.5); 133 788 (68.0%), normal weight (BMI, 18.5-24.9); 38 828 (19.7%), overweight (BMI, 25.0-29.9); 11 992 (6.1%), obesity grade 1 (BMI, 30.0-34.9); 3284 (1.7%), obesity grade 2 (BMI, 35.0-39.9); and 969 (0.5%), obesity grade 3 (BMI, ≥40.0) (Table) . Overall, any adverse outcome occurred in 37.2% (n = 73 161) of women, ranging from 34.7% (2706 of 7809) among women categorized as underweight to 61.1% (592 of 969) among women categorized as obesity grade 3.
Women who gained more gestational weight had a lower maternal prepregnancy BMI and were slightly younger and more often nulliparous than multiparous (eTable 2 in the Supplement). There were no missing data for any individual b Based on cohort-specific criteria. Each cohort used their own country-specific criteria to define low, medium, and high educational level. These 3 categories were subsequently used in the meta-analysis.
c These rows have missing data.
d Defined as gestational hypertension plus proteinuria.
e Defined as systolic blood pressure of 140 mm Hg or higher, diastolic blood pressure of 90 mm Hg or higher, or both after 20 weeks of gestation in previously normotensive women.
f Defined as either a random glucose level greater than 11.0 mmol/L, a fasting glucose level of 7.0 mmol/L or greater, or a fasting glucose level between 6.1 and 6.9 mmol/L with a subsequent abnormal glucose tolerance test (glucose level >7.8 mmol/L after glucose intake).
g Defined as gestational age at birth of less than 37 weeks.
h Small was defined as sex-and gestational age-adjusted birth weight less than the 10th percentile; large, greater than the 90th percentile.
i Weight was included at the highest age available for each child (median, 84.9 [quartile 1 and quartile 3, 61.9 and 95.9] months). Underweight based on sex-and age-adjusted SD scores of less than −2.0 for children aged 2 to 5 years and for those older than 5 years; overweight, SD scores greater than 2.0 for children aged 2 to 5 years and greater than 1.0 for those older than 5 years.
j Includes preeclampsia, gestational hypertension, gestational diabetes, cesarean delivery, preterm birth, and small or large size for gestational age at birth.
adverse outcome for 169 437 women (86.2%). Of the remainder, 17 093 women (8.7%) were missing data for gestational hypertensive disorders (including preeclampsia and gestational hypertension), 6898 (3.5%) for gestational diabetes, 9786 (5.0%) for cesarean delivery, 8541 (4.3%) for preterm birth, and 6453 (3.3%) for size (small or large) for gestational age at birth (eTable 3 in the Supplement). Based on the profiles of all included cohorts, the percentage of women included with multiple singleton pregnancies is about 1%.
Participant Characteristics in Validation Sample
There were 3505 women included in the validation sample. They had a median age of 31.0 years (quartile 1 and 3, 27.7 and 34.7 years) and 1696 were white. There were 277 women (7.9%) categorized as underweight; 2400 (68.5%), normal weight; 577 (16.5%), overweight; 188 (5.4%), obesity grade 1; 53 (1.5%), obesity grade 2; and 10 (0.3%), obesity grade 3. Any adverse outcome occurred in 1423 women (40.6%; eTable 4 in the Supplement). There were no missing data for any individual adverse outcome for 3059 women (87.3%). Of the remainder, 423 women (12.1%) were missing data for gestational hypertensive disorders (including preeclampsia and gestational hypertension), 421 (12.0%) for gestational diabetes, 15 (0.4%) for cesarean delivery, 426 (12.2%) for preterm birth, and 7 (0.2%) for size (small or large) for gestational age at birth (eTable 3 in the Supplement). eTables 5 and 6 in the Supplement provide cohortspecific information for both the main sample and the validation sample.
Maternal Prepregnancy BMI, Gestational Weight Gain, and Absolute Risk for Any Adverse Outcome
The absolute risk for any adverse outcome increased across the full range of maternal prepregnancy BMI and was largely independent of gestational weight gain (Figure 1) . The lowest absolute risks were observed among women with low to normal BMI and a moderate to high total gestational weight gain. The lowest risk was 26.7% (16 of 60) for women with a BMI of less than 18.0 and gestational weight gain of 26.0 kg to 27.9 kg. The highest absolute risks were observed among women with a high BMI and a high gestational weight gain. The highest risk was 94.4% (17 of 18) for women with a BMI of 40.0 or greater and gestational weight gain of 20.0 kg to 21.9 kg.
Among women categorized as underweight, the absolute risk for any adverse outcome ranged from 29.2% (387 of 1326) for gestational weight gain of 14.0 kg to 15.9 kg to 50.2% (203 of 404) for gestational weight gain of less than 8.0 kg (Figure 2) . Of all outcomes separately, the absolute risk was highest for small size for gestational age (highest risk: 32.1% [125 of 390] for gestational weight gain <8 kg).
Among women categorized as normal weight, the absolute risk for any adverse outcome ranged from 31.7% (7314 of 23 073) for gestational weight gain of 14.0 kg to 15.9 kg to 46.9% (1256 of 2679) for gestational weight gain of 28.0 kg or greater and was highest at both extremes of gestational weight gain.
Among women categorized as overweight, the absolute risk for any adverse outcome increased from 37.3% (249 of 667) for gestational weight gain of 2.0 kg to 3.9 kg to 56.4% (624 of 1107) Among women categorized as obesity grade 1, 2, or 3, the absolute risk for any adverse outcome increased across the range of gestational weight gain. The highest absolute risks were 63.7% (160 of 251) for gestational weight gain of 28.0 kg or greater in 18.5-24.9), overweight (25.0-29.9 ), obesity grade 1 (30.0-34.9), obesity grade 2 (35.0-39.9), and obesity grade 3 (Ն40.0). Any adverse outcome includes preeclampsia (gestational hypertension plus proteinuria), gestational hypertension (systolic blood pressure Ն140 mm Hg, diastolic blood pressure Ն90 mm Hg, or both after 20 weeks of gestation in previously normotensive women), gestational diabetes (a random glucose level >11.0 mmol/L, a fasting glucose level Ն7.0 mmol/L, or a fasting glucose level between 6.1 and 6.9 mmol/L with a subsequent abnormal glucose tolerance test [glucose level >7.8 mmol/L after glucose intake]), cesarean delivery, preterm birth (gestational age at birth <37 weeks), and small or large size for gestational age at birth (sex-and gestational age-adjusted birth weight <10th percentile and >90th percentile, respectively). The odds ratios for the risk of any adverse outcome were 1.28 (95% CI, 1.27-1.29) and 1.04 (95% CI, 1.03-1.05) per 1-SD increase in maternal prepregnancy body mass index and gestational weight gain, respectively (P < .001 for comparison). The number of cases for each outcome and the total number of participants in each gestational weight gain category appears in eTable 7 in the Supplement.
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women categorized as obesity grade 1, 67.7% (384 of 567) for gestational weight gain of 16.0 kg or greater in women categorized as obesity grade 2, and 78.8% (93 of 118) for gestational weight gain of 16.0 kg or greater in women categorized as obesity grade 3. The association of maternal prepregnancy BMI with the risk for any adverse outcomes was stronger than the association of gestational weight gain. The ORs for the risk of any adverse outcome were 1.28 (95% CI, 1.27-1.29) and 1.04 (95% CI, 1.03-1.05) per 1-SD increase in maternal prepregnancy BMI and gestational weight gain, respectively (P<.001 for comparison). The absolute data for each gestational weight gain category appear in eTable 7 in the Supplement.
Optimal Gestational Weight Gain per Clinical BMI Group
The optimal gestational weight gain ranges associated with the lowest risks for any adverse outcome appear in Figure 3 . Among women categorized as underweight, the optimal gestational weight gain range was 14.0 kg to less than 16.0 kg, with corresponding OR and absolute risk reduction (ARR; the percentage reduction in absolute risk of any adverse outcome) of 0.74 (95% CI, 0.65-0.84) and 0.07% (95% CI, 0.04%-0.09%), respectively. Among women categorized as normal weight, the optimal gestational weight gain range was 10.0 kg to less than 18.0 kg ( . The ORs and ARRs for each gestational weight gain category used to determine the optimal ranges appear in eTable 8 and eTable 9 in the Supplement, respectively. The gestational weight gain ranges defined in this study and the NAM ranges appear in eTable 10 in the Supplement. The gestational weight gain ranges in this study were roughly comparable with the NAM ranges for underweight, normal weight, and overweight, and were lower for all obesity grades. This study classified 11.3% of women (n = 22 236) in the main sample as having inadequate gestational weight gain and 33.8% of women (n = 66 463) as having excessive gestational weight gain. The NAM categories classified 21.5% of women (n = 42 323) as having inadequate gestational weight gain and 42.0% of women (n = 82 544) as having excessive gestational weight gain. Gestational weight gain outside the ranges from the current study and the NAM ranges was associated with adverse outcomes (eFigure 2 and eFigure 3 in the Supplement). Each classification system had a low to moderate ability to distinguish between those with and those without adverse outcomes (range for AUROC, 0.55-0.77; eFigure 4 in the Supplement).
Sensitivity Analyses
The sensitivity analyses, in which optimal gestational weight gain was determined based on protective associations regardless of statistical significance, resulted in broader ranges of optimal gestational weight gain (eFigure 5 in the Supplement). Optimal gestational weight gain ranges similar to those from the main analyses were observed when length of gestation was considered and when participants with missing individual outcome data were excluded (eTable 11 in the Supplement). In addition, the sensitivity analyses showed that optimal weight gain definitions were not altered by including or excluding preterm birth, cesarean delivery, childhood underweight or overweight, gestational diabetes, and preeclampsia as adverse outcomes or by adjusting for maternal age and parity (eTable 11 in the Supplement).
Of all the women classified as having excessive gestational weight gain during the full pregnancy, 84.6% also would be classified as having excessive weight gain during the first half of the pregnancy (eFigure 6, eTable 12, and eTable 13 in the Supplement). Results for the validation sample showed that the discriminative performance of the optimal gestational weight gain ranges developed in this study and the weight gain ranges from the NAM guidelines were consistent with findings in the main study sample (range for AUROC, 0.50-0.79; eTable 14, eFigure 7, and eFigure 8 in the Supplement).
Discussion
Maternal prepregnancy BMI, and to a lesser extent gestational weight gain, are associated with risks of adverse maternal and infant adverse outcomes. Gestational weight gain ranges that were associated with lower risks for adverse outcomes were 14.0 kg to less than 16.0 kg for women categorized as being underweight; 10.0 kg to less than 18.0 kg for normal weight; 2.0 kg to less than 16.0 kg for overweight; 2.0 kg to less than 6.0 kg for obesity grade 1; weight loss or gain of 0 kg to less than 4.0 kg for obesity grade 2; and weight gain of 0 kg to less than 6.0 kg for obesity grade 3.
Gestational weight gain outside these ranges was associated with adverse outcomes. However, discriminative performance of gestational weight gain with adverse maternal and infant outcomes was low to moderate. Prepregnancy BMI was more strongly associated with adverse maternal and infant outcomes than the amount of gestational weight gain.
Prepregnancy BMI is significantly associated with pregnancy complications and offspring obesity and also is associated with gestational weight gain. 5, 6 Results from this study suggest that maternal prepregnancy BMI was more strongly associated with adverse maternal and infant outcomes than gestational weight gain. Therefore, prepregnancy BMI may be an important focus for preconception counseling. Previous studies that attempted to define optimal gestational weight gain associated with fewer adverse outcomes differed considerably among study populations, statistical approaches, outcomes, and conclusions regarding optimal gestational weight gain ranges. 14, [16] [17] [18] [19] [20] [21] [22] Only 1 study of 120 251 obese US women defined optimal gestational weight gain ranges OR indicates odds ratio and it reflects the risk for any adverse outcome per gestational weight gain category for women with underweight, normal weight, overweight, obesity grade 1, obesity grade 2, and obesity grade 3, parts A-F, respectively, compared with all other gestational weight gain categories in that specific group for clinical maternal body mass index (BMI; calculated as weight in kilograms divided by height in meters squared). The solid circles represent the OR for all participants in each gestational weight gain category. The error bars indicate 95% CIs. The blue area represents the optimal gestational weight gain range according to the current analysis, the gray area represents the gestational weight gain ranges recommended by the US National Academy of Medicine (NAM; formerly the Institute of Medicine). The gestational weight gain categories were 2 kg each. Participants in the extreme categories of gestational weight gain had values beyond the most extreme labeled tick marks. The maternal BMI categories were underweight (<18.5), normal weight (18.5-24.9), overweight (25.0-29.9), obesity grade 1 (30.0-34.9), obesity grade 2 (35.0-39.9), and obesity grade 3 (Ն40.0). Any adverse outcome includes preeclampsia (gestational hypertension plus proteinuria), gestational hypertension (systolic blood pressure Ն140 mm Hg, diastolic blood pressure Ն90 mm Hg, or both after 20 weeks of gestation in previously normotensive women), gestational diabetes (a random glucose level >11.0 mmol/L, a fasting glucose level Ն7.0 mmol/L, or a fasting glucose level between 6.1 and 6.9 mmol/L with a subsequent abnormal glucose tolerance test [glucose level >7.8 mmol/L after glucose intake]), cesarean delivery, preterm birth (gestational age at birth <37 weeks), and small or large size for gestational age at birth (sex-and gestational age-adjusted birth weight <10th percentile and >90th percentile, respectively). For the gestational weight gain ranges defined in this study, a statistically significant OR lower than 1 for a gestational weight gain category was considered the optimal weight gain. If a nonsignificant association (either with an OR >1, <1, or of 1) for a gestational weight gain category was surrounded by 2 significant estimates with an OR below 1, that gestational weight gain category was included in the optimal gestational weight gain range. The number of cases for each outcome and the total number of participants in each gestational weight gain category appear in eTable 7 in the Supplement. The optimal gestational weight gain ranges based only on protective associations appear in eFigure 5 in the Supplement.
Research Original Investigation
Association of Gestational Weight Gain With Adverse Maternal and Infant Outcomes according to maternal obesity grade 1 (4.5 kg-11.3 kg), obesity grade 2 (0 kg-4.1 kg), and obesity grade 3 (weight loss <4 kg), and that study used data from term births only.
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Compared with prior work, the present study focused on common and important adverse maternal and infant outcomes, included women from multiple Western countries, and compared the associations of gestational weight gain and prepregnancy BMI with adverse outcomes. Consistent with the NAM guidelines, this study used total gestational weight gain to identify optimal gestational weight gain ranges instead of gestational weight gain per week because gestational weight gain does not have a linear pattern. 7, 8 Total gestational weight gain is dependent in part on pregnancy duration. The observed results were similar after adjustment for gestational age at birth and after excluding preterm births. Consistent with the NAM guidelines, this study showed that among women with higher prepregnancy BMI, lower gestational weight gain was associated with fewer adverse outcomes. Gestational weight gain ranges for women categorized as obesity grade 1, 2, or 3 were lower than the NAM guidelines and even involved weight loss for severely obese women, although neither classification was predictive for adverse outcomes. However, the results for severely obese women should be interpreted with caution because the optimal gestational weight gain ranges for obesity grades 1 through 3 associated with better outcomes fluctuate and do not follow a clear linear trend. These results may represent the relatively small sample size of obese women and lack of statistical power rather than biological plausibility. Future studies should evaluate the effect and safety of weight loss during pregnancy in severely obese women. Gestational weight gain guidelines are used in several Western countries for preconception counseling. The gestational weight gain ranges developed in this study classified fewer women as having suboptimal weight gain compared with the NAM guidelines. However, the discriminative performance, as indicated by the AUROC, was weak for both classification systems. This suggests that the use of gestational weight gain guidelines may need to be reconsidered for individual prediction of the risk for adverse outcomes. Future research should assess whether optimal gestational weight gain ranges combined with other maternal and fetal pregnancy characteristics are useful for prediction of adverse outcomes.
The findings from this study suggest that prepregnancy weight might be a more important target for interventions than gestational weight gain. Previous studies of dietary and physical activity interventions for pregnant women have not shown an effect on pregnancy outcomes. [23] [24] [25] [26] Based on current evidence, future clinical trials designed to reduce weight-related maternal and infant adverse outcomes should focus on maternal weight before or at the start of pregnancy.
Limitations
This study has several limitations. First, not all invited cohorts were able to participate in the current analyses. Second, the analyses did not measure changes in the association of gestational weight gain with adverse outcomes over time. The results may be biased if the association of gestational weight gain with adverse outcomes changed over time. Third, data on prepregnancy weight was mainly self-reported, and the latest weight during pregnancy was either self-reported or measured. This may have led to misclassification of gestational weight gain. Fourth, the composite outcome of any adverse outcome might have been misclassified as a result of some missing data for individual outcomes. Fifth, all outcomes were considered equally important and the analyses did not account for the differences in outcome severity. Sixth, cesarean delivery may be due to many factors and may not be an appropriate outcome for studying associations of weight change with adverse maternal outcomes. 7 Seventh, information on stillbirth was not available. Eighth, optimal gestational weight gain was defined as a protective association with the risk for any adverse outcome, reflecting the best outcome possible and limiting the number of participants incorrectly classified as having adequate gestational weight gain. The ranges would be slightly broader if optimal gestational weight gain was defined as no increased risk for adverse outcomes, which includes both a protective association and a null association. Ninth, the analyses were not adjusted for multiple testing. Tenth, as a result of the limited sample sizes for underweight and severely obese women, heterogeneity was not assessed. Eleventh, based on the profiles of all the included cohorts, about 1% of women were included more than once for multiple pregnancies. Twelfth, for some outcomes, discriminative performance in the validation sample was lower than in the main sample, potentially resulting from overfitting of the models in the main sample.
Conclusions
In this meta-analysis of pooled individual participant data from 25 cohort studies, the risk for adverse maternal and infant outcomes varied by gestational weight gain and across the range of prepregnancy weights. The estimates of optimal gestational weight gain may inform prenatal counseling; however, the optimal gestational weight gain ranges had limited predictive value for the outcomes assessed. 
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Sciences were only involved in the design of the birth outcomes phase of the FCOU study. All of the other funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. In this issue of JAMA, the LifeCycle Project-Maternal Obesity and Childhood Outcomes Study Group 3 reports the results of an individual patient-level meta-analysis in which the amount of gestational weight gain associated with fewer adverse pregnancy outcomes was defined according to prepregnancy BMI. Even though the amount of optimal weight gain during pregnancy varied according to prepregnancy BMI, gestational weight gain had only low to moderate discriminative performance for adverse outcomes. In contrast, prepregnancy BMI values above normal were strongly associated with higher rates of adverse outcomes. These associations were observed regardless of the amount of gestational weight gain. Thus, an important conclusion of the report by Voerman et al 3 is that prepregnancy BMI was more strongly associated with adverse maternal and infant outcomes than the amount of gestational weight gain. Obesity affects 40% of women in the United States.
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Ensuring that pregnancies result in healthy mothers and infants is an important public health goal. Based on the study by Voerman et al, 3 resources should be dedicated toward ensuring an optimal BMI for all women of reproductive age rather than on gestational weight gain. 5 Recent guidelines and available services can help achieve this important public health goal.
5,6
Author Affiliations: Values represent odds ratios (95% Confidence Intervals) reflecting the risk of adverse maternal or infant outcome in women with inadequate and excessive weight gain as compared to women with adequate weight gain, according to this study (red triangles) and IOM (US Institute of Medicine, nowadays called National Academy of Medicine (NAM)) classification (black dots), per clinical BMI category. Inadequate and excessive gestational weight gain are defined as gestational weight gain below or above the ranges defined by this study and IOM, respectively (eTable 10). Any adverse outcome includes pre-eclampsia (PE), gestational hypertension (PIH), gestational diabetes (GDM), caesarean section, preterm birth, and small size-for-gestational-age (SGA), large size-for-gestational-age (LGA). Low and high birth weight and childhood under-and overweight were not included for the definition of the optimal weight gain ranges. * P-value for the difference between ORs for this study and IOM (calculated using Z= (logodds This study -logodds IOM) /sqrt(SEThis study 2 +SEIOM 2 )).
eFigure 3 (continued). Associations of inadequate and excessive gestational weight gain by classifications from this study and IOM with adverse maternal and infant outcomes. by clinical body mass index group
Values represent odds ratios (95% Confidence Intervals) reflecting the risk of adverse maternal or infant outcome in women with inadequate and excessive weight gain as compared to women with adequate weight gain, according to this study (red triangles) and IOM (US Institute of Medicine, nowadays called National Academy of Medicine (NAM)) classification (black dots), per clinical BMI category. Inadequate and excessive gestational weight gain are defined as gestational weight gain below or above the ranges defined by this study and IOM, respectively (eTable 10). Any adverse outcome includes pre-eclampsia (PE), gestational hypertension (PIH), gestational diabetes (GDM), caesarean section, preterm birth, and small size-for-gestational-age (SGA), large size-for-gestational-age (LGA). Low and high birth weight and childhood under-and overweight were not included for the definition of the optimal weight gain ranges. * P-value for the difference between ORs for this study and IOM (calculated using Z= (logodds This study -logodds IOM) /sqrt(SEThis study 2 +SEIOM 2 )).
eFigure 4. Receiver operator characteristic curves of inadequate and excessive gestational weight gain by classifications from this study and IOM for the detection of adverse maternal and infant outcomes Abbreviations: AUC, area under the Receiver Operator Characteristic curve; IOM, US Institute of Medicine (nowadays called National Academy of Medicine (NAM)). Inadequate and excessive gestational weight gain are defined as gestational weight gain below or above the ranges defined by this study and IOM, respectively (eTable 10). Any adverse outcome includes pre-eclampsia (PE), gestational hypertension (PIH), gestational diabetes (GDM), caesarean section, preterm birth, small size-forgestational-age (SGA), and large size-for-gestational-age (LGA). Low and high birth weight and childhood under-and overweight were not included for the definition of the optimal weight gain ranges.
eFigure 4 (continued). Receiver operator characteristic curves of inadequate and excessive gestational weight gain by classifications from this study and IOM for the detection of adverse maternal and infant outcomes Abbreviations: AUC, area under the Receiver Operator Characteristic curve; IOM, US Institute of Medicine (US Institute of Medicine, nowadays called National Academy of Medicine (NAM)). Inadequate and excessive gestational weight gain are defined as gestational weight gain below or above the ranges defined by this study and IOM, respectively (eTable 10). Any adverse outcome includes pre-eclampsia (PE), gestational hypertension (PIH), gestational diabetes (GDM), caesarean section, preterm birth, small size-for-gestational-age (SGA), and large size-for-gestational-age (LGA). Low and high birth weight and childhood under-and overweight were not included for the definition of the optimal weight gain ranges.
eFigure 5. Associations of gestational weight gain categories with any adverse outcome per maternal clinical body mass index group, ranges from this study based on protective associations only
The symbols represent odds ratios (95% Confidence Intervals) reflecting the risk of any adverse outcome per gestational weight gain category for women with (A) underweight, (B) normal weight, (C) overweight, (D) obesity grade 1, (E) obesity grade 2 and (F) obesity grade 3, as compared to all other gestational weight gain categories in that specific clinical maternal body mass index group. The symbols represent the mean for all participants in each gestational weight gain category. The percentages below each of the figures represent the number of participants in that gestational weight gain category as a percentage of all participants within that BMI category. Participants in the extreme categories of gestational weight gain had values beyond the most extreme labeled tick marks. Any adverse outcome includes preeclampsia, gestational hypertension, gestational diabetes, caesarean section, preterm birth, small size-for-gestational-age, and large size-for-gestational-age. This figure is equal to Figure 3 , but shows ranges from this study when optimal weight gain would be defined as all associations below 1, regardless of statistical significance. The red area represents the optimal weight gain range according to this study, the grey area represents the weight gain ranges as recommended by the US Institute of Medicine (IOM, nowadays called National Academy of Medicine (NAM)).
eFigure 6. Associations of categories of gestational weight gain in first half of pregnancy with any adverse outcome per maternal clinical body mass index group
The symbols represent odds ratios (95% Confidence Intervals) reflecting the risk of any adverse outcome per category of gestational weight gain in first half of pregnancy for women with (A) underweight, (B) normal weight, (C) overweight, (D) obesity grade 1, (E) obesity grade 2 and (F) obesity grade 3, as compared to all other gestational weight gain categories in that specific clinical maternal body mass index group. The percentages below each of the figures represent the number of participants in that gestational weight gain category as a percentage of all participants within that BMI category. The symbols represent the mean for all participants in each gestational weight gain category. Participants in the extreme categories of gestational weight gain had values beyond the most extreme labeled tick marks. Because of the relatively low levels of gestational weight gain in first half of pregnancy, we categorized weight gain within this time interval into categories of 1 kg each. Any adverse outcome includes pre-eclampsia, gestational hypertension, gestational diabetes, caesarean section, preterm birth, small size-for-gestational-age, and large size-for-gestational-age. The red area represents the optimal weight gain range according to the current analysis. No optimal weight gain range was observed for obesity grade 3 due to low numbers.
eFigure 7. Associations of inadequate and excessive gestational weight gain by classifications from this study and IOM with adverse maternal and infant outcomes, hospital-based population (used as validation sample)
Abbreviations: IOM, US Institute of Medicine (nowadays called National Academy of Medicine (NAM)). Values represent odds ratios (OR) (95% Confidence Intervals (CI)) reflecting the risk of adverse maternal and infant outcomes in women with inadequate and excessive weight gain as compared to women with adequate weight gain, according to this study (red triangles) and IOM classifications (black dots). Inadequate and excessive gestational weight gain are defined as gestational weight gain below or above the ranges from this study and IOM, respectively (eTable 14).Any adverse outcome includes pre-eclampsia (PE), gestational hypertension (PIH), gestational diabetes (GDM), caesarean section, preterm birth, small size-for-gestational-age (SGA), and large size-for-gestational-age (LGA). Low and high birth and childhood under-and overweight were not included for the definition of the optimal weight gain ranges. * P-value for the difference between ORs for this study and IOM (calculated using Z= (logodds This study -logodds IOM) /sqrt(SEThis study 2 +SEIOM 2 )). b Body mass index is calculated as weight in kilograms divided by height in meters squared. c Education level was based on cohort-specific criteria. Each cohort used their own country-specific criteria to define low, medium and high educational level. These 3 categories were subsequently used in the meta-analysis. d Gestational hypertension is defined as systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg after 20 weeks of gestation in previously normotensive women. e Pre-eclampsia is defined as gestational hypertension plus proteinuria. f Gestational diabetes is defined as either a random glucose level >11.0 mmol/L, a fasting glucose level ≥7.0 mmol/L or a fasting glucose level between 6.1 and 6.9 mmol/L with a subsequent abnormal glucose tolerance test (glucose level >7.8 mmol/L after glucose intake). g Preterm birth is defined as gestational age at birth <37 weeks. h Small size-for-gestational-age at birth is defined as sex-and gestational age adjusted birth weight <10 th percentile. i Large size-for-gestational-age at birth is defined as sex-and gestational age adjusted birth >90 th percentile. j Childhood underweight at the highest age available for each child (median (Q1, Q3): 84.9 (61.9, 95.9) months) is defined as sex-and age adjusted standard deviation scores (SDS) <-2 SDS for children of 2-5 years of age, and <-2 SDS for children of >5 years. k Childhood overweight at the highest age available for each child (median (Q1, Q3): 84.9 (61.9, 95.9) months) is defined as sex-and age adjusted standard deviation scores (SDS) >2.0 SDS for children of 2-5 years of age, and >1 SDS for children of >5 years. l Any adverse outcome includes pre-eclampsia, gestational hypertension, gestational diabetes, caesarean section, preterm birth, small size-forgestational-age, and large size-for-gestational-age. a Values are median (Q1, Q3), median (P2.5, P97.5) or n (valid %). b NA: not available (not collected or not provided). c Body mass index is calculated as weight in kilograms divided by height in meters squared. d Education level was based on cohort-specific criteria. Each cohort used their own country-specific criteria to define low, medium and high educational level. These 3 categories were subsequently used in the meta-analysis. e Subset of participants with 4-years follow-up completed.
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